To study the impact of hospital safety-net burden on survival and the receipt of trimodality therapy, with chemoradiation (CRT) followed by surgery, for patients with esophageal cancer. The National Cancer Database was queried for patients diagnosed with non-metastatic esophageal squamous cell carcinoma (SCC) or adenocarcinoma from 2004-2013. Hospitals were categorized based on the percentage of uninsured/Medicaid-insured patients treated at each facility, with hospitals in the 0-38thpercentile defined as no safety-net burden hospitals (NBH), hospitals in the 39-75thpercentiles defined as low safety-net burden hospitals (LBH), and hospitals at the 75thpercentile or above defined as high safety-net burden hospitals (HBH). Adjusted odds ratios (aOR) with 95% confidence intervals (CI) were computed for receipt of surgery following CRT, vs. CRT alone. Cox regression modeling was used to calculate adjusted hazard ratios (aHR) for survival. There were 460 NBH, 420 LBH, and 281 HBH identified with 3,139, 11,094, and 3,631 patients, respectively. The median percentage of uninsured/Medicaid patients treated was 0% (range 0-0%) at NBH, 8.9% (range 1.5-16.7%) at LBH, and 25.0% (range 17.2-100%) at HBH. Only 9.8% of NBH were classified as academic/research programs, compared to 25.2% of LBH and 24.6% of HBH. Patients treated at HBH were more likely to be black, have incomes <$30,000, and have SCC histology with clinical Stage III-IVa disease (Table). Median follow-up in all and surviving patients was 19.2 and 40.6 months, respectively. Median survival was 21.5 months, and the overall 5-year survival was 24.8%. On both univariate analysis and multivariate analysis, adjusting for age, gender, race, Hispanic origin, income, comorbidities, insurance status, stage, histology, primary site, facility type and volume, treatment, and time to treatment, there was no significant survival difference after treatment at HBH (aHR 1.01; 95% CI 0.95-1.07, p=0.75) or LBH (aHR 1.02; 95% CI 0.97-1.08, p=0.38) compared to NBH. Odds of receiving surgery following CRT did not vary by safety-net burden (HBH vs. NBH: aOR 0.94; 95% CI 0.83-1.06, p=0.31; LBH vs. NBH: aOR 0.95; 95% CI 0.86-1.06, p=0.36). Safety-net burden did not impact survival or receipt of trimodality therapy on subgroup analyses stratified by histology or stage. High safety-net burden hospitals were more likely to treat esophageal patients with lower socioeconomic status and adverse clinicopathologic risk factors, without adversely impacting survival or the receipt of trimodality therapy, irrespective of tumor histology and stage.Abstract 2439; Table 1Selected patient and tumor characteristics by hospital safety-net burdenNBHLBHHBHp-valueBlack race171 (5.5%)948 (8.6%)717 (19.8%)<0.0001Income <$30,000284 (9.1%)1,385 (12.5%)851 (23.4%)<0.0001SCC1,055 (33.6%)3,540 (31.9%)1,617 (44.5%)<0.0001Stage III-IVa1,415 (45.1%)5,034 (45.4%)1,795 (49.4%)<0.0001 Open table in a new tab